SUPERNUS PHARMACEUTICALS, INC.
In the published model solve dated 2026-Q2, anchored at $46.97, SUPERNUS PHARMACEUTICALS, INC. (SUPN) is priced for +15.3% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 11, 2026 from SEC EDGAR filings.
• Supernus has rebuilt itself around growth assets: first-quarter revenue rose 39 percent to $207.7 million, led by the non-stimulant ADHD drug Qelbree (up 20 percent to $77.9 million) and $27.6 million of ZURZUVAE collaboration revenue from the Sage acquisition [Source: company Q1 2026 results, May 2026]. • The balance sheet is a rarity in mid-cap pharma, $384 million of cash against zero funded debt with a share count that has edged down, so the growth is self-funded and acquisition capacity r
Is SUPN overvalued? See what's priced in →
313 institutional managers reported holding SUPN in 13F filings for the quarter ended 2026-03-31. 36 opened new positions that quarter. Held by BlackRock, Vanguard Group, Millennium Management, among others. On the short side, 6.1M shares were sold short as of the 2026-06-15 count, about 11% of shares outstanding (10.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
SUPN's share count grew 8.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at SUPN over the trailing three years. Absence is a fact about the company, not a signal. 11 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
SUPN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-10 | -0.2% | -16.9% |
| 2023-08-09 | -5.3% | -11.4% |
| 2023-11-09 | +9.6% | +6.0% |
| 2024-05-09 | -3.7% | -5.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
SUPN's latest 8-K filings: 2026-08-03 (items 8.01, 9.01); 2026-08-03 (items 8.01, 9.01); 2026-08-03 (items 2.02, 9.01); 2026-08-03 (items 1.01, 5.02, 8.01, 9.01); 2026-07-22 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.